The activation of the hepatocyte growth factor/mesenchymal–epithelial transition (MET) pathway is implicated in the progression of glioblastoma, as it activates downstream signaling events including Ras/Raf/MAPK, STAT3, and PI3K/AKT/mTOR. Here, MTOR is linked to glioblastoma.